AQP4 and systemic lupus erythematosus: Data on the safety of eculizumab in such patients are limited thus far, but further research is important considering that eculizumab is increasingly being used to treat AQP4-IgG-positive NMOSD and that NMOSD is frequently associated with other autoimmune diseases that may comprise immune function (most commonly SLE) [4, 20].